曲美他嗪对冠心病合并糖尿病患者介入治疗术中及术后缺血的影响

Influence of trimetazidine on myocardial ischemic of the patients of CAD with Diabetes melitus in and post PCI

目的评价经皮冠状动脉介入治疗(PCI)之前使用曲美他嗪对冠心病伴糖尿病患者术中及术后心肌缺血程度的影响。方法对确诊糖尿病合并心绞痛准备行PTCA术134例患者随机分为术前口服曲美他嗪实验组和对照组,进行相关对比研究。结果球囊充气时平均ST段抬高或降低实验组低于对照组,充气到ST段抬高或减低的时间、充气到发生心绞痛的平均时间实验组高于对照组,放气到心绞痛缓解的平均时间实验组低于对照组,术后实验组CK-MB、TNI、CRP低于对照组,以上比较均有显著性差异。结论术前口服曲美他嗪可提高冠心病合并糖尿病患者对心肌缺血的耐受程度,并有助于术中减少心绞痛的发生,提高手术的安全性,减少术后心肌缺血的发生。

Objective Value trimetazidine impact on PCI of the patient CAD with Diabetes mellitus.Methods 134 cases patients with coronary disease with diabetes mellitus before undergoing PCI were randomly divided into the routine treatment group and trimetazidine group two groups,then relative comparative study was made.Results ST elevation or decrease on ballon pumping were significant reduced than routine treatment group,From ballon pumping to ST elevation or decrease time were significant increased than routine treatment group,From ballon pumping to angina time were also significant increased than routine treatment group,From ballon decreasing pressure to angina ending time were significant decreased than routine treatment group,CK-MB,TNI and CRP were significant decreased than routine treatment group.Conclusion Trimetazidine can improve myocardial ischemic tolerance,reduce angina attacts of PCI patients with diabetes mellitus in operation,and make operation more safe,and reduce myocardial ischemic post operation.